Search - tctmd.com

Displaying 1 - 20 of 93

Sort: Relevancy | Date

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

November 03, 2025

Solid 2-Year Data With ‘Unlocking’ Coronary Stent: BIOADAPTOR RCT

News Conference News EuroPCR 2024

Solid 2-Year Data With ‘Unlocking’ Coronary Stent: BIOADAPTOR RCT

Michael O'Riordan

May 28, 2024

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

News Conference News TCT 2023

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

Michael O'Riordan

November 01, 2023

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

News Conference News TCT 2023

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

October 27, 2023

Newest Resorbable Magnesium Scaffold Shows Promise in BIOMAG-1

News Conference News EAS 2023

Newest Resorbable Magnesium Scaffold Shows Promise in BIOMAG-1

Michael O'Riordan

May 25, 2023

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

News Conference News

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

March 02, 2022

Good Long-term Results With FANTOM BVS, but More Data Needed

News Conference News TCT 2021

Good Long-term Results With FANTOM BVS, but More Data Needed

Michael O'Riordan

October 21, 2021

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

News Conference News EuroPCR 2021

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

May 24, 2021

FUTURE II: A Good ‘First Step’ for Thinner-Strut Bioresorbable Scaffold

News Conference News EuroPCR 2021

FUTURE II: A Good ‘First Step’ for Thinner-Strut Bioresorbable Scaffold

Michael O'Riordan

May 19, 2021

The Skinny on Ultrathin DES: Meta-analysis Shows Some Long-term Advantages

News Conference News EuroPCR 2021

The Skinny on Ultrathin DES: Meta-analysis Shows Some Long-term Advantages

May 19, 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

News Conference News CRT 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

March 16, 2021

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

News Conference News TCT 2020

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

October 17, 2020

October 2020 News Roundup

News Opinion CV Team Dispatch

October 2020 News Roundup

October 01, 2020

Newer, Thinner-Strut Abbott Scaffold Prompts Talk of a BVS Comeback

News Conference News CRT 2020

Newer, Thinner-Strut Abbott Scaffold Prompts Talk of a BVS Comeback

Michael O'Riordan

February 28, 2020

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

News Conference News CRT 2020

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

February 25, 2020

News Industry News

Two-year data shows trend towards lower target vessel failure with Indian stent Supraflex vs. Xience stent from Abbott

October 09, 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

News Daily News TCT 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

October 02, 2019

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

News Conference News TCT 2019

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

Michael O'Riordan

September 30, 2019

The Case for Further Reducing Strut Thickness: Technical Challenges and Clinical Benefits

Presentation TCT 2019

The Case for Further Reducing Strut Thickness: Technical Challenges and Clinical Benefits

Presenter: Sripal Bangalore

September 26, 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

News Conference News ESC 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

September 10, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.